Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 11 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Sorafenib for the treatment of advanced hepatocellular carcinoma
NICE TA189
SorafenibNot recommended26 May 2010Replaced by TA474
Human growth hormone (somatropin) for the treatment of growth failure in children
NICE TA188
SomatropinRecommended26 May 2010Current
Infliximab and adalimumab for the treatment of Crohn's disease
NICE TA187
Infliximab, AdalimumabRecommended19 May 2010Current
Certolizumab pegol for the treatment of rheumatoid arthritis
NICE TA186
Certolizumab PegolOptimised24 Feb 2010Replaced by TA375
Trabectedin for the treatment of advanced soft tissue sarcoma
NICE TA185
TrabectedinRecommended24 Feb 2010
Updated 8 Feb 2021
Current
Topotecan for the treatment of relapsed small-cell lung cancer
NICE TA184
TopotecanRecommended Not recommended25 Nov 2009Current
Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA183
TopotecanRecommended28 Oct 2009Current
Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
NICE TA182
PrasugrelRecommended28 Oct 2009Replaced by TA317
Pemetrexed for the first-line treatment of non-small-cell lung cancer
NICE TA181
PemetrexedRecommended23 Sep 2009Current
Ustekinumab for treating moderate to severe plaque psoriasis
NICE TA180
UstekinumabRecommended23 Sep 2009
Updated 3 Mar 2017
Current
Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA179
SunitinibRecommended23 Sep 2009Current
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
NICE TA178
Bevacizumab, Sorafenib, Temsirolimus, SunitinibNot recommended26 Aug 2009Current
Alitretinoin for the treatment of severe chronic hand eczema
NICE TA177
—Recommended26 Aug 2009Current
Cetuximab for the first-line treatment of metastatic colorectal cancer
NICE TA176
CetuximabRecommended26 Aug 2009Current
Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)
NICE TA175
GefitinibTerminated (no company submission)22 Jul 2009Current
Rituximab for the first-line treatment of chronic lymphocytic leukaemia
NICE TA174
RituximabOptimised22 Jul 2009Current
Tenofovir disoproxil for the treatment of chronic hepatitis B
NICE TA173
Tenofovir Disoproxil FumarateRecommended22 Jul 2009Current
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
NICE TA172
CetuximabNot recommended24 Jun 2009Current
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
NICE TA171
LenalidomideRecommended18 Jun 2009
Updated 26 Jun 2019
Current
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery
NICE TA170
RivaroxabanRecommended22 Apr 2009Current
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA169
SunitinibRecommended25 Mar 2009Current
Amantadine, oseltamivir and zanamivir for the treatment of influenza
NICE TA168
Amantadine, OseltamivirRecommended Not recommended25 Feb 2009Current
Endovascular stent–grafts for the treatment of abdominal aortic aneurysms
NICE TA167
—Recommended Only in research25 Feb 2009Current
Cochlear implants for children and adults with severe to profound deafness
NICE TA166
—Recommended Optimised Not recommended28 Jan 2009Current
Machine perfusion systems and cold static storage of kidneys from deceased donors
NICE TA165
—Recommended28 Jan 2009Current
Febuxostat for the management of hyperuricaemia in people with gout
NICE TA164
FebuxostatRecommended17 Dec 2008Current
Infliximab for acute exacerbations of ulcerative colitis
NICE TA163
InfliximabRecommended17 Dec 2008Current
Erlotinib for the treatment of non-small-cell lung cancer
NICE TA162
ErlotinibRecommended Not recommended26 Nov 2008
Updated 1 Dec 2012
Current
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA161
Alendronate, Etidronate, TeriparatideRecommended Optimised27 Oct 2008
Updated 7 Feb 2018
Current
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160
Alendronate, EtidronateOptimised Not recommended27 Oct 2008
Updated 7 Feb 2018
Current
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin
NICE TA159
—Only in research Optimised22 Oct 2008Current
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
NICE TA158
Amantadine, OseltamivirNot recommended Recommended24 Sep 2008Current
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery
NICE TA157
Dabigatran EtexilateRecommended24 Sep 2008Current
Routine antenatal anti-D prophylaxis for women who are rhesus D negative
NICE TA156
—Recommended27 Aug 2008Current
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
NICE TA155
RanibizumabRecommended Not recommended27 Aug 2008
Updated 20 May 2024
Current
Telbivudine for the treatment of chronic hepatitis B
NICE TA154
—Not recommended27 Aug 2008Current
Entecavir for the treatment of chronic hepatitis B
NICE TA153
EntecavirRecommended27 Aug 2008Current
Drug-eluting stents for the treatment of coronary artery disease
NICE TA152
—Optimised23 Jul 2008
Updated 18 Nov 2020
Current
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
NICE TA151
—Optimised23 Jul 2008Current
Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy
NICE TA150
CetuximabTerminated (no company submission)25 Jun 2008Current
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
NICE TA149
—Terminated (no company submission)25 Jun 2008Current
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
NICE TA148
BevacizumabTerminated (no company submission)25 Jun 2008Current
Bevacizumab for the first-line treatment of metastatic breast cancer
NICE TA147
BevacizumabTerminated (no company submission)25 Jun 2008Current
Adalimumab for treating moderate to severe plaque psoriasis
NICE TA146
AdalimumabRecommended25 Jun 2008Current
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
NICE TA145
CetuximabOptimised25 Jun 2008Current
Rimonabant for the treatment of overweight and obese adults
NICE TA144
—Optimised23 Jun 2008Current
Adalimumab, etanercept and infliximab for ankylosing spondylitis
NICE TA143
Adalimumab, Etanercept, InfliximabRecommended Not recommended28 May 2008Replaced by TA383
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia
NICE TA142
—Optimised28 May 2008Replaced by TA323
Abatacept for the treatment of rheumatoid arthritis
NICE TA141
AbataceptNot recommended23 Apr 2008Current
Infliximab for subacute manifestations of ulcerative colitis
NICE TA140
InfliximabNot recommended23 Apr 2008Replaced by TA329
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome
NICE TA139
—Recommended26 Mar 2008
Updated 20 Aug 2021
Current
Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
NICE TA138
BudesonideRecommended26 Mar 2008Current
Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma
NICE TA137
RituximabRecommended27 Feb 2008Current
Structural neuroimaging in first-episode psychosis
NICE TA136
—Not recommended27 Feb 2008Current
Pemetrexed for the treatment of malignant pleural mesothelioma
NICE TA135
PemetrexedRecommended23 Jan 2008Current
Infliximab for treating moderate to severe plaque psoriasis
NICE TA134
—Optimised23 Jan 2008Current
Omalizumab for severe persistent allergic asthma
NICE TA133
OmalizumabRecommended28 Nov 2007Replaced
Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
NICE TA132
EzetimibeRecommended28 Nov 2007Current
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years
NICE TA131
BudesonideRecommended28 Nov 2007Current
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
NICE TA130
Adalimumab, Etanercept, InfliximabNot recommended Optimised22 Oct 2007Replaced by TA375
Bortezomib monotherapy for relapsed multiple myeloma
NICE TA129
BortezomibRecommended23 Oct 2007Current
Stapled haemorrhoidopexy for the treatment of haemorrhoids
NICE TA128
—Recommended26 Sep 2007Current
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis
NICE TA127
NatalizumabOptimised22 Aug 2007
Updated 21 May 2024
Current
Rituximab for the treatment of rheumatoid arthritis
NICE TA126
RituximabRecommended22 Aug 2007Current
Adalimumab for the treatment of psoriatic arthritis
NICE TA125
AdalimumabRecommended22 Aug 2007Current
Pemetrexed for the treatment of non-small-cell lung cancer
NICE TA124
PemetrexedNot recommended22 Aug 2007Current
Varenicline for smoking cessation
NICE TA123
VareniclineRecommended25 Jul 2007Current
Alteplase for the treatment of acute ischaemic stroke
NICE TA122
AlteplaseRecommended27 Jun 2007Replaced by TA264
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
NICE TA121
TemozolomideRecommended27 Jun 2007Current
Cardiac resynchronisation therapy for the treatment of heart failure
NICE TA120
—Recommended23 May 2007Replaced by TA314
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
NICE TA119
FludarabineNot recommended28 Feb 2007Current
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
NICE TA118
Bevacizumab, CetuximabNot recommended24 Jan 2007
Updated 1 Jan 2012
Current
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
NICE TA117
—Optimised24 Jan 2007Current
Gemcitabine for the treatment of metastatic breast cancer
NICE TA116
GemcitabineRecommended24 Jan 2007Current
Naltrexone for the management of opioid dependence
NICE TA115
NaltrexoneRecommended24 Jan 2007Current
Methadone and buprenorphine for the management of opioid dependence
NICE TA114
Buprenorphine, MethadoneRecommended24 Jan 2007Current
Inhaled insulin for the treatment of type 1 and type 2 diabetes
NICE TA113
—Optimised13 Dec 2006Current
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
NICE TA112
Anastrozole, Exemestane, LetrozoleRecommended22 Nov 2006Current
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
NICE TA111
Donepezil, Galantamine, MemantineOptimised Only in research22 Nov 2006Current
Rituximab for the treatment of follicular lymphoma
NICE TA110
RituximabRecommended27 Sep 2006Replaced by TA243
Docetaxel for the adjuvant treatment of early node-positive breast cancer
NICE TA109
DocetaxelRecommended26 Sep 2006Current
Paclitaxel for the adjuvant treatment of early node-positive breast cancer
NICE TA108
PaclitaxelNot recommended27 Sep 2006Current
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
NICE TA107
TrastuzumabRecommended23 Aug 2006Current
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
NICE TA106
Peginterferon alfa-2bRecommended23 Aug 2006
Updated 27 Nov 2013
Current
Laparoscopic surgery for colorectal cancer
NICE TA105
—Recommended23 Aug 2006Current
Etanercept and infliximab for the treatment of psoriatic arthritis
NICE TA104
Etanercept, InfliximabRecommended Optimised26 Jul 2006Replaced by TA199
Etanercept and efalizumab for treating moderate to severe plaque psoriasis
NICE TA103
EtanerceptOptimised Recommended26 Jul 2006
Updated 1 Sep 2009
Current
Parent-training/education programmes in the management of children with conduct disorders
NICE TA102
—Recommended26 Jul 2006Current
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
NICE TA101
DocetaxelRecommended28 Jun 2006Current
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer
NICE TA100
Capecitabine, OxaliplatinRecommended26 Apr 2006Current
Immunosuppressive therapy for renal transplantation in children and adolescents
NICE TA99
Basiliximab, Sirolimus, Tacrolimus, Mycophenolate MofetilNot recommended Recommended Optimised26 Apr 2006Current
Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
NICE TA98
Atomoxetine, MethylphenidateRecommended22 Mar 2006Current
Computerised cognitive behaviour therapy for depression and anxiety
NICE TA97
—Not recommended Recommended Only in research22 Feb 2006Withdrawn
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
NICE TA96
—Optimised Recommended22 Feb 2006Current
Implantable cardioverter defibrillators for arrhythmias
NICE TA95
—Recommended25 Jan 2006Replaced by TA314
Statins for the prevention of cardiovascular events
NICE TA94
Atorvastatin, Pravastatin, Rosuvastatin, SimvastatinRecommended25 Jan 2006Current
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed
NICE TA93
Irinotecan, Oxaliplatin, RaltitrexedRecommended Only in research24 Aug 2005Current
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries)
NICE TA92
—Only in research27 Jul 2005Current
Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
NICE TA91
Pegylated liposomal doxorubicin, Topotecan, PaclitaxelRecommended25 May 2005Replaced by TA389
Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events
NICE TA90
Dipyridamole, ClopidogrelOptimised25 May 2005Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.